Message from the Director
“Welcome to the second edition of our newsletter. Our goal is to continue publishing these newsletters on a regular basis to help the lymphoma community remain abreast of the recent activities of WCMC researchers.”
Lymphoma Program Highlights
We believe that the future of oncology lies in targeted, non-chemotherapy drugs. Over the past decade, WCMC has contributed to the FDA approval of multiple new lymphoma drugs, including ibrutinib and idelalisib over the past year. The following are short summaries of some of our recent success stories.
Clinical Trial Spotlight
This is a select list of our open trials. Currently there are over 30 open trials for various lymphomas at WCMC. A complete listing of our offerings can be found at: http://cornellmedicine.com/trials/
- Phase I trial of ibrutinib + palbociclib in patients with previously treated mantle cell lymphoma: this is a WCMC investigator-initiated trial that seeks to evaluate the safety and activity of the ibrutinib and palbociclib combination in patients with previously treated mantle cell lymphoma.
- Phase I study of ACP 196 in patients with Waldenstrom’s Macroglobulinemia: this trial seeks to evaluate the safety and efficacy of ACP-196 for patients with Waldenstrom’s Macroglobulinemia to determine the effective dose portion of ACP-196.
- Phase I study of EZH2 inhibitor GSK2816126 in patients with relapsed/refractory diffuse large B-cell & transformed follicular lymphoma: this two part trial seeks to determine the most effective tolerated dose of GSK2816126 and then the effects of the agent on the EZH2 mutation.
A current WCMC patient writes about his experience in seeking treatment with the Lymphoma Program at WCMC.
“In February of 2011 I was diagnosed with lymphoma while I was in Florida. I contacted my primary care physician, and he immediately arranged for my care with Dr. Jia Ruan of the Lymphoma Program. Two days later I flew to New York and Dr. Ruan diagnosed my disease more specifically as mantle cell lymphoma.” Click here for the full article